Found 278 matching trials
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy PHASE4 The purpose of this study is to investigate the efficacy and safety of long...
Show More Location
Kameda Medical Center
Learn More & Join Trial
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients PHASE3 The purpose of this study is to compare a standard chemotherapy regimen of ...
Show More Location
112 sites UK wide
Treatments Being Tested
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) Learn More & Join Trial
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment PHASE2 This study will test how effective the drug, Carfilzomib, reduces progressi...
Show More Location
Birmingham VA Medical Center
Learn More & Join Trial
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia NA This pilot clinical trial studies the feasibility of choosing treatment bas...
Show More Location
Fred Hutch/University of Washington Cancer Consortium
Learn More & Join Trial
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma PHASE2 Patients included in the study will receive induction treatment during 6 mo...
Show More Status
Active Not Recruiting
Location
Hospital Clínic de Barcelona
Learn More & Join Trial
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma PHASE2 Background:
Advanced urothelial cancer has no cure. But only a few chemoth...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation PHASE2 The clinical trial is a Phase II open label, single-arm pilot study to eval...
Show More Location
University of Pittsburgh Medical Center
Learn More & Join Trial
Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting N/A Since 2009, the Department of Clinical Haematology at Limoges University Ho...
Show More Learn More & Join Trial
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) PHASE3 This study is researching a drug called linvoseltamab (also called "study d...
Show More Location
Emory Winship Cancer Institute
Learn More & Join Trial
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients PHASE3 The primary objective of this study was to compare progression-free surviva...
Show More Location
Providence St. Joseph Medical Center
Learn More & Join Trial